EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications

Shaminie J. Athinarayanan, Alison R. Zoller, Kristin E. Bergethon, Amy M. Goss, Barbara A. Gower

Nutrients · 20.11.2026 · 18 (22) · 3877

DOI: 10.3390/nu18223877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, online erschienen am 20.11.2026. Verfasst von Shaminie J. Athinarayanan und 4 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Incretin-based obesity medications (IOMs) produce substantial weight loss, but the added benefit of structured nutritional therapy remains unclear. We compared 12-month weight loss between individualized carbohydrate-reduced nutritional therapy plus IOMs (VINT + IOM) and IOM-based care without structured nutritional therapy (IOM only).

Methods

In this retrospective cohort study of 4269 adults in a telemedicine obesity care program (VINT + IOM, n = 1658; IOM only, n = 2611), both pathways included clinician-guided medication management and behavioral coaching. The primary analysis included GLP-1-naïve participants on a single ingredient (semaglutide or tirzepatide). Adjusted weight change was estimated using longitudinal linear mixed-effects models.

Results

Retention through 12 months was 77% (VINT + IOM) vs. 72% (IOM only). In GLP-1-naïve semaglutide users, adjusted 12-month weight loss was greater with VINT + IOM than IOM only (13.9 vs. 10.9 kg; difference 3.0 kg, 95% CI 0.6–5.4; p = 0.012); observed loss was 13.3% vs. 11.1%. In tirzepatide users, adjusted loss was 20.8 vs. 15.6 kg (difference 5.2 kg, 95% CI 1.8–8.7; p = 0.003); observed loss was 19.7% vs. 15.6%. Responder rates favored VINT + IOM. In the overall cohort, adjusted loss was 13.3 vs. 9.8 kg (p < 0.001), and the advantage persisted among participants with prior GLP-1 exposure. Weight loss continued between 6 and 12 months, and approximately 80% of participants in both pathways had an IOM proportion of days covering ≥80%. Self-reported side effects were similar (63.6% vs. 64.6%).

Conclusions

Adding individualized carbohydrate-reduced nutritional therapy to IOM-based care was associated with greater 12-month weight loss than IOM-based care without structured nutritional therapy. These real-world findings support further evaluation of individualized nutrition as an adjunct to incretin-based pharmacotherapy.

Zitieren

APA

Athinarayanan, S. J., Zoller, A. R., Bergethon, K. E., Goss, A. M., & Gower, B. A. (2026). Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications. Nutrients, 18(22), 3877. https://doi.org/10.3390/nu18223877

Vancouver

Athinarayanan SJ, Zoller AR, Bergethon KE, Goss AM, Gower BA. Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications. Nutrients. 2026;18(22):3877. doi:10.3390/nu18223877

BibTeX
@article{Athinarayanan2026,
  author = {Athinarayanan, Shaminie J. and Zoller, Alison R. and Bergethon, Kristin E. and Goss, Amy M. and Gower, Barbara A.},
  title = {Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3877},
  doi = {10.3390/nu18223877}
}
Kostenlos starten →